Kexing Biopharm Co., Ltd. (SHA:688136)

Market Cap	5.97B +62.1%
Revenue (ttm)	1.54B +9.5%
Net Income	159.44M +406.5%
EPS	0.81 +406.3%
Shares Out	198.11M
PE Ratio	37.23
Forward PE	27.67
Dividend	0.08 (0.28%)
Ex-Dividend Date	n/a

Volume	2,909,091
Average Volume	2,708,336
Open	28.76
Previous Close	28.76
Day's Range	28.53 - 30.20
52-Week Range	20.05 - 63.99
Beta	0.73
RSI	44.32
Earnings Date	Mar 28, 2026

About Kexing Biopharm

Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05 human interferon a1b in...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 971
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688136

Financial Performance

In 2025, Kexing Biopharm's revenue was 1.54 billion, an increase of 9.54% compared to the previous year's 1.41 billion. Earnings were 159.44 million, an increase of 406.47%.